Search Results - "Co, Melannie"

P1084: LONG‐TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB‐3111‐214) TRIAL by Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim, Mckay, Pam, Leitch, Sophie, Jin, Jie, Sun, Mingyuan, Sobieraj‐Teague, Magdalena, Luigi Zinzani, Pier, Browett, Peter, Thieblemont, Catherine, Marina Liberati, Anna, Bachy, Emmanuel, Cavallo, Federica, Costello, Régis, Iyengar, Sunil, Marasca, Roberto, Mociková, Heidi, Seok Kim, Jin, Talaulikar, Dipti, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith

Get full text

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma by Opat, Stephen, Tedeschi, Alessandra, Linton, Kim, McKay, Pamela, Hu, Bei, Chan, Henry, Jin, Jie, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Coleman, Morton, Thieblemont, Catherine, Browett, Peter, Ke, Xiaoyan, Sun, Mingyuan, Marcus, Robert, Portell, Craig A, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A, Mapp, Sally, Ho, Shir-Jing, Talaulikar, Dipti, Zhou, Ke-Shu, Co, Melannie, Li, Xiaotong, Zhou, Wenxiao, Cappellini, Massimo, Tankersley, Chris, Huang, Jane, Trotman, Judith

“…Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We…”
Get full text

Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) by Opat, Stephen, Marcus, Robert, Portell, Craig Anthony, Reed, William, Co, Melannie, Huang, Jane, Trotman, Judith

“…Abstract only TPS7568 Background: Bruton tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling, mediating B-cell proliferation, migration,…”
Get full text

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma by Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia

“…Summary This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously…”
Get full text

Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL) by Dreyling, Martin H., Tam, Constantine Si Lun, Wang, Michael, Smith, Stephen Douglas, Ladetto, Marco, Huang, Huiqiang, Elstrom, Rebecca L., Co, Melannie, Holmgren, Eric, Huang, Jane, Le Gouill, Steven

“…Abstract only TPS8071 Background: Bruton tyrosine kinase (BTK) mediates B-cell proliferation, migration, and adhesion. BTK inhibition has emerged as a strategy…”
Get full text

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial by Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M., McKay, Pamela, Chan, Henry, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Browett, Peter J., Ke, Xiaoyan, Portell, Craig A., Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza, Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith

Get full text

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) by Shortt, Jake, Montesinos, Pau, Tan, Shuh Ying, Fong Ng, Teng, Fong, Chun Yew, Cannell, Paul, Rajagopal, Rajeev, Leitch, Sophia, Tan, Peter T., Ramanathan, Sundra, Gasiorowski, Robin, Lenton, Douglas Stuart, Teh, Tse-Chieh, Pérez-Simón, José Antonio, Grove, Carolyn, Huang, Xiaojun, DiNardo, Courtney D., Naidu, Katherine, Pariseau, Joseph, Cheng, Si, Liu, Yu, Co, Melannie, Chan, Wai Y., Guo, Haiyi, Wei, Andrew H.

Get full text

A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma by Dreyling, Martin, Tam, Constantine S, Wang, Michael, Smith, Stephen D, Ladetto, Marco, Huang, Huiqiang, Novotny, William, Co, Melannie, Romano, Alfredo, Holmgren, Eric, Huang, Jane, Gouill, Steven Le

“…Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable…”
Get full text

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial by Opat, Stephen, Tedeschi, Alessandra, Linton, Kim, McKay, Pamela, Hu, Bei, Chan, Henry, Jin, Jie, Zinzani, Pier Luigi, Browett, Peter, Coleman, Morton, Sobieraj-Teague, Magdalena, Ke, Xiaoyan, Sun, Mingyuan, Marcus, Robert, Portell, Craig A., Zhou, Keshu, Thieblemont, Catherine, Co, Melannie, Wang, Weige, Tankersley, Chris, Zhou, Wenxiao, Cappellini, Massimo, Huang, Jane, Trotman, Judith

“…Background: Marginal zone lymphoma (MZL) is rare and heterogeneous and it has been difficult to define optimal therapeutic strategies. Like other indolent…”
Get full text

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma by Tatarczuch, Maciej, Waltham, Mark, Shortt, Jake, Polekhina, Galina, Hawkes, Eliza A., Ho, Shir-Jing, Trotman, Judith, Brasacchio, Daniella, Co, Melannie, Li, Jessica, Ramakrishnan, Vanitha, Dunne, Karin, Opat, Stephen S., Gregory, Gareth P.

“…•Molecular profiling of MZL may assist in the rational use of BTK inhibitor therapy.•BTK and PLCG2 mutations confer acquired resistance of MZL to BTK…”
Get full text

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study by Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M, McKay, Pamela, Leitch, Sophie, Coleman, Morton, Zinzani, Pier Luigi, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Browett, Peter, Ke, Xiaoyan, Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A, Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith

“…The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK)…”
Get full text

The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma by Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Co, Melannie, Neuenburg, Jutta K., Goy, Andre

“…Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) typically have poor treatment outcomes, especially patients who are…”
Get full text

132 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial by Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M, McKay, Pamela, Chan, Henry, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Browett, Peter, Ke, Xiaoyan, Portell, Craig A., Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith

Get full text

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial by Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M, McKay, Pamela, Chan, Henry, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Browett, Peter, Ke, Xiaoyan, Portell, Craig A., Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, Trotman, Judith

Get full text

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens by Eron, Joseph J, Lalezari, Jay, Slim, Jihad, Gathe, Joseph, Ruane, Peter J, Wang, Chia, Elion, Richard, Blick, Gary, Khatri, Amit, Hu, Yiran B, Gibbons, Krystal, Fredrick, Linda, Co, Melannie, D'Amico, Ronald, Da Silva‐Tillmann, Barbara, Trinh, Roger, Sulkowski, Mark S

“…Objective Whether concomitant HIV antiretroviral therapy (ART) affects the safety and efficacy of interferon‐free HCV therapies or whether HCV treatment may…”
Get full text